| Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib S Jagannathan, MAY Abdel-Malek, E Malek, N Vad, T Latif, KC Anderson, ... Leukemia 29 (11), 2184-2191, 2015 | 115 | 2015 |
| MiR-29b replacement inhibits proteasomes and disrupts aggresome+ autophagosome formation to enhance the antimyeloma benefit of bortezomib S Jagannathan, N Vad, S Vallabhapurapu, KC Anderson, JJ Driscoll Leukemia 29 (3), 727-738, 2015 | 78 | 2015 |
| Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice SK Kudugunti, NM Vad, E Ekogbo, MY Moridani Investigational new drugs 29, 52-62, 2011 | 71 | 2011 |
| Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines SK Kudugunti, NM Vad, AJ Whiteside, BU Naik, MA Yusuf, ... Chemico-biological interactions 188 (1), 1-14, 2010 | 54 | 2010 |
| Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma E Malek, MAY Abdel-Malek, S Jagannathan, N Vad, R Karns, AG Jegga, ... Leukemia 31 (3), 645-653, 2017 | 53 | 2017 |
| Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines NM Vad, G Yount, D Moore, J Weidanz, MY Moridani Journal of pharmaceutical sciences 98 (4), 1409-1425, 2009 | 41 | 2009 |
| Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines NM Vad, G Yount, MY Moridani Melanoma Research 18 (6), 386-399, 2008 | 34 | 2008 |
| Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice MMY Vad NM, Kudugunti SK, Wang H, Bhat GJ Tumour Biol. 35 (5), 4967-76, 2014 | 25* | 2014 |
| Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice NM Vad, SK Kudugunti, H Wang, GJ Bhat, MY Moridani Tumor Biology 35, 4967-4976, 2014 | 25 | 2014 |
| Structure–toxicity relationship of phenolic analogs as anti-melanoma agents: An enzyme directed prodrug approach NM Vad, PK Kandala, SK Srivastava, MY Moridani Chemico-biological interactions 183 (3), 462-471, 2010 | 18 | 2010 |
| Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice NM Vad, SK Kudugunti, D Graber, N Bailey, K Srivenugopal, MY Moridani International journal of oncology 35 (1), 193-204, 2009 | 16 | 2009 |
| Metabolic bioactivation and toxicity of ethyl 4-hydroxybenzoate in human SK-MEL-28 melanoma cells NM Vad, IH Shaik, R Mehvar, MY Moridani Journal of Pharmaceutical Sciences 97 (5), 1934-1945, 2008 | 16 | 2008 |
| Abstract# 678: Biochemical mechanism of rutin toxicity in SK-MEL-28 melanoma cells: A tyrosinase bioactivation prodrug approach N Vad, B Naik, M Moridani Cancer Research 69 (9_Supplement), 678-678, 2009 | 2 | 2009 |
| Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101 A Scholz, J DeFalco, Y Leung, IT Aydin, CJ Czupalla, W Cao, D Santos, ... Proceedings of the National Academy of Sciences 119 (19), e2123483119, 2022 | 1 | 2022 |
| Metformin suppresses GRP78-dependent PI3-Kinase activity in clonogenic side population to enhance the anti-myeloma benefit of bortezomib JJ Driscoll, S Jagannathan, MAY Abdel Malek, N Vad, E Malek Cancer Research 75 (15_Supplement), 4242-4242, 2015 | 1 | 2015 |
| Long non-coding RNAs deregulated in Multiple Myeloma impact therapeutic response to proteasome inhibitors E Malek, R Karns, AG Jegga, S Jagannathan, N Vad, MAY Abdel Malek, ... Cancer Research 75 (15_Supplement), 153-153, 2015 | 1 | 2015 |
| TM-03THE HSP90 INHIBITOR GANETESPIB IS AN EFFECTIVE THERAPY FOR GLIOBLASTOMA THAT BLOCKS EGFR-DRIVEN TUMOR GROWTH J Driscoll, N Vad, S Jagannathan Neuro-Oncology 16 (Suppl 5), v213, 2014 | 1 | 2014 |
| SC-31RATIONAL DESIGN OF A PI3-KINASE/mTOR INHIBITOR CYTOTOXIC TO BRAIN CANCER STEM CELLS UNDER HYPOXIA N Vad, S Jagannathan, K Sumita, M Abdel-Malek, J Driscoll Neuro-Oncology 16 (Suppl 5), v203, 2014 | 1 | 2014 |
| Antibodies that bind tumor tissue for diagnosis and therapy J DeFalco, DE Emerling, J Finn, NM Greenberg, V Huang, SM Lippow, ... US Patent App. 17/935,152, 2023 | | 2023 |
| 1194 Discovery and pre-clinical development of a novel and differentiated EphA2-targeted antibody in multiple bispecific formats M Bhatti, M Weiss, A Haltom, J Finn, A Gai, A Ye, D Zhang, C Czupalla, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
